15th Mar 2021 10:44
Cap-XX Ltd - Australia-based supercapacitors and energy management systems manufacturer - Says Portal Instruments selects its supercapacitors for needle-free drug delivery platform for self-administering biological medicines.
"Portal Instruments chose the CAP-XX prismatic supercapacitors, which are manufactured in CAP-XX's production facilities in Australia and Malaysia, due to their characteristic low equivalent series resistance which enables the high burst of energy needed to drive the fast, large volume needle-free jet injection, and for their thin form factor which fits easily inside the small drug delivery device," company says.
Portal Instruments' needle-free jet injection platform is intended to simplify the drug delivery experience, from self-injection for patients suffering from chronic disease, to healthcare workers delivering vaccines.
"We are proud to provide the high-density power Portal Instruments needs to inject high viscosity biologics without the pain and anxiety of needles," says Anthony Kongats, Cap-XX chief executive.
Current stock price: 8.14 pence; up 3.6% on Monday
Year-to-date change: down 39%
By Paul McGowan; [email protected] and Lucy Heming;Â [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
CAP-XX